Neuronetics, Inc. (STIM)
| Market Cap | 42.18M |
| Revenue (ttm) | 72.71M |
| Net Income (ttm) | -36.42M |
| Shares Out | 30.35M |
| EPS (ttm) | -1.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,929 |
| Open | 1.270 |
| Previous Close | 1.290 |
| Day's Range | 1.260 - 1.420 |
| 52-Week Range | 0.520 - 5.070 |
| Beta | 2.25 |
| Analysts | Buy |
| Price Target | 4.67 (+235.97%) |
| Earnings Date | Nov 12, 2024 |
About STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of... [Read more]
Financial Performance
In 2023, Neuronetics's revenue was $71.35 million, an increase of 9.42% compared to the previous year's $65.21 million. Losses were -$30.19 million, -18.76% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for STIM stock is "Buy." The 12-month stock price forecast is $4.67, which is an increase of 235.97% from the latest price.
News
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to a new employee as described below. In accordance w...
Neuronetics and Greenbrook TMS Announce Closing of Transaction
MALVERN, Pa. and TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”, and together with Neuronetics, the ...
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life...
Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President and Chief Executive Officer Steve...
CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ: STIM), please note that in the second paragraph of the "Stockhol...
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming ...
Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life...
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
Data selected for oral presentation reinforce previous findings on safety and efficacy Data selected for oral presentation reinforce previous findings on safety and efficacy
Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings
MALVERN, Pa. and TORONTO , Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that the Ontario Superio...
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
Policy update increases access for millions covered by HCSC BlueCross BlueShield policies Policy update increases access for millions covered by HCSC BlueCross BlueShield policies
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patient...
NeuroStar® Releases Software Upgrades to Elevate Patient Care
Upgrades improve communication, streamline data management, and strengthen security Upgrades improve communication, streamline data management, and strengthen security
NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives
Neuronetics, Inc. (STIM) Q2 2024 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Keith Sullivan - President & CEO Steve Furlong - CFO Mark Klausner - IR Conference Cal...
Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations
On Monday, Neuronetics Inc. STIM, a provider of noninvasive treatments for psychiatric disorders, agreed to acquire Greenbrook TMS Inc. GBNHF in an all-stock transaction.
Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge
MALVERN, Pa. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”) today announced that they have ente...
Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming ...
NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
New initiative aims to provide information and resources for teen mental health amidst rising public health concerns New initiative aims to provide information and resources for teen mental health ami...
Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors
MALVERN, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life...
Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life...
Aetna Policy Update Expands TMS Availability for Adolescents With Depression
Coverage criteria consistent with recent FDA clearance for NeuroStar TMS Coverage criteria consistent with recent FDA clearance for NeuroStar TMS
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal
BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents
Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health
NeuroStar® Launches Better Me Provider Program Nationwide
The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry The first and only TMS company to establish comprehensive standard...
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024 Early prediction of nonresponse abstract selected for oral presentation as a prest...